The Clinical Observation Of Recombinant Streptokinase Joint Clopidogrel For Patients With Acute Myocardial Infarction

Objective:The aim of study was to observe the safety and clinical efficacy of domestic recombinant streptokinase joint clopidogrel in patients with acute myocardial infarctionMethods:One hundred forty-five patients with acute myocardial infarction which had been treated by r-SK from the cardiovascular department in My Hospital during october 2003 to january 2008 were admitted to the clinical trial group.They were divided into two groups by using clopidogrel or not.There were 70 patients in clopidogrel group,75 patients were in control group.On admission cases(145cases),the clinical characteristies,thrombolytic vascular reperfusion rate, recurrent myocardial ischemia,reinfarction within 30 days,hemorrhage and cardiovascular death events were observed.Adverse reactions were also observed.The reperfusion rate of infarct-related coronary artery was assessed by unified clinical criteria.Patients received clopidogrel at a dose of 300 mg as an initial loading dose before the thromblytic therapy,then followed by 75 mg once daily.In the two groups,there were 33 cases to have accepted the therapy of elected coronary intervention(PCI),clopidogrel group had 18 cases which had accepted elected PCI.Results:Clinical baseline information of the two groups had no significant difference. Clopidogrel group has higher vascular reperfusion rate(86.9%vs.71.2%,χ~2 =5.263, P=0.022).30 day mortality rate(1.4%vs12%,χ~2=4.763,P=0.029),non-fatal myocardial infarction(0%vs.10.7%,χ~2=5.989,P=0.014),Both were lower than the controlled group.On recurrent myocardial ischemia and the incidence of slight bleeding,the two groups showed no significant difference(2.9%vs.5.3%,χ~2 =0.109,P=0.741;3.7%vs.6.3%,χ~2＜0.001,P= 0.999). Hemorrhagic stroke rate were also no significant difference between the two groups(0%vs.1.3 %,χ~2＜0.001,P=0.999).No anaphylactic reaction and other severe adverse events related to drug therapy were noted.Conclusion:It is safe and effective to treat AMI patients with domestic recombinant streptokinase joint clopidogrel.